# First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)

> **NCT04747197** · PHASE1 · COMPLETED · sponsor: **EyePoint Pharmaceuticals, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** EYP-1901

## Key facts

- **NCT ID:** NCT04747197
- **Lead sponsor:** EyePoint Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-05-11
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04747197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04747197, "First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04747197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*